DRRX DURECT Corporation

+0.03  (+5%)
Previous Close 0.63
Open 0.66
Price To Book 7.28
Market Cap 106,443,171
Shares 162,359,931
Volume 997,053
Short Ratio
Av. Daily Volume 744,033

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced July 27, 2018.
Phase 2 top-line data due 2H 2019.
CRL issued February 12, 2014.
Post-operative pain relief
CRL Feb 12 2014. Phase 3 commenced November 2015 in response to CRL. Noted October 19, 2017 that primary endpoint was not met. NDA to be refiled 2Q 2019.
Post-operative pain relief
Phase 3 to be initiated by ZGNX once partner is found.
Phase 2 initial data due 2H 2019.
Nonalcoholic steatohepatitis (NASH)
Phase 2 preliminary data noted May 8, 2019.
Alcoholic hepatitis (AH)

Latest News

  1. DURECT Announces $15 Million Registered Direct Offering
  2. DURECT Announces Completion of the 90 mg Severe Cohort and Dose Escalation Committee Approval to Commence 150 mg Dosing in Patients with Severe Alcoholic Hepatitis (AH) in its Ongoing DUR-928 Phase 2a AH Trial
  3. Edited Transcript of DRRX earnings conference call or presentation 8-May-19 12:30pm GMT
  4. DRRX: Highly Compelling Initial Ph2a DUR-928 Alcoholic Hepatitis Data. Final Data Later This Year Could Be Value Inflection Event
  5. DURECT to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019
  6. DURECT Corporation Announces Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial
  7. The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split
  8. DURECT Corp. to Host Earnings Call
  9. Durect: 1Q Earnings Snapshot
  10. DURECT Corporation Announces First Quarter 2019 Financial Results and Update of Programs
  11. The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex
  12. DURECT Corporation to Present Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial and Report First Quarter 2019 Financial Results
  13. DURECT Appoints Two New Board Members
  14. DURECT Corporation (NASDAQ:DRRX): What's The Analyst Consensus Outlook?
  15. DURECT to Present at the H.C. Wainwright Global Life Sciences Conference and Host an Upcoming KOL call on NASH
  16. DURECT Announces Patient Enrollment in Phase 1b Clinical Trial of Oral DUR-928 in Patients with Non-Alcoholic Steatohepatitis (NASH)
  17. DURECT Announces Patient Dosing in Phase 2a Proof-of-Concept Clinical Trial of Topical DUR-928 in Patients with Mild to Moderate Plaque Psoriasis